AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31419427 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise
Number of subjects: 0
Study 28481882 — intervention group
Group type: COMPARATOR
Intervention: 800 IU vitamin D3 daily for 6 months (Supplementation Study)
Number of subjects: 348
Study 28481882 — intervention group
Group type: COMPARATOR
Intervention: 300 IU vitamin D3 daily in fortified milk for 7 weeks (Fortification Study)
Number of subjects: 348
Study 28481882 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (both studies)
Number of subjects: 348
Study 28481882 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (Fortification Study)
Number of subjects: 348
Study 25297721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate cream (0.05%) applied at home
Number of subjects: 109
Study 25297721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silver nitrate (99%) in the outpatient clinic
Number of subjects: 109
Study 25297721 — intervention group
Group type: COMPARATOR
Intervention: Ethanol wipes (82%) at home
Number of subjects: 109
Study 23107870 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol plus bepridil
Number of subjects: 144
Study 23107870 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan plus bepridil
Number of subjects: 144
Study 23107870 — intervention group
Group type: COMPARATOR
Intervention: Bepridil alone
Number of subjects: 144
Study 21771340 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week worksite-based yoga program, delivered three times per week during lunch hour, led by an experienced yoga instructor.
Number of subjects: 0
Study 21771340 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group.
Number of subjects: 0
Study 19786670 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus anastrozole
Number of subjects: 207
Study 19786670 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole alone
Number of subjects: 207
Study 16338019 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily for 48 weeks
Number of subjects: 209
Study 16338019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 14984391 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment with cognitive‐behaviour therapy and coping training
Number of subjects: 63
Study 14984391 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 63
Study 11346245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase therapy
Number of subjects: 32
Study 9412633 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 28
Study 9412633 — intervention group
Group type: COMPARATOR
Intervention: Carotid percutaneous transluminal angioplasty (PTA)
Number of subjects: 28
Study 8434556 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 0.5 g twice daily
Number of subjects: 0
Study 8434556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3628103 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic insoles used in work shoes for five weeks
Number of subjects: 100
Study 3628103 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 29680079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor health workshop
Number of subjects: 50
Study 29680079 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 50
Study 27650295 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron plus TIVA (palonosetron 0.075 mg i.v.)
Number of subjects: 100
Study 27650295 — intervention group
Group type: COMPARATOR
Intervention: TIVA (normal saline 1.5 ml i.v.)
Number of subjects: 100
Study 27650295 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron plus TIVA
Number of subjects: 100
Study 27650295 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 100
Study 24010809 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-cellulite cosmetic applied for 6 weeks
Number of subjects: 20
Study 22397815 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg genistein daily for 3-6 weeks
Number of subjects: 47
Study 22397815 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 47
Study 20108098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with high proportion of phytate-rich foods
Number of subjects: 0
Study 20108098 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet with low proportion of phytate-rich foods
Number of subjects: 0
Study 18236302 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored smoking cessation intervention based on the transtheoretical model; involved up to three individualized feedback letters.
Number of subjects: 611
Study 18236302 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 611
Study 16180527 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic short-term psychotherapy (PSTP) - 25 sessions
Number of subjects: 20
Study 16180527 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 20
Study 16180527 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic short-term psychotherapy (PSTP)
Number of subjects: 20
Study 12559286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic breast irradiation (RT) with mostly single fraction (12 to 15 Gy) electrons
Number of subjects: 253
Study 12559286 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic breast irradiation (no-RT)
Number of subjects: 253
Study 12559286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic breast irradiation (RT)
Number of subjects: 253
Study 10595786 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg/day)
Number of subjects: 69
Study 10595786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (15 mg/day)
Number of subjects: 69
Study 10595786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (15 mg/day)
Number of subjects: 69
Study 8951132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 (PGE2) gel (0.5 mg) followed by insertion of a 24-Foley catheter
Number of subjects: 78
Study 8951132 — intervention group
Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 (PGE2) gel (two doses of 0.5 mg)
Number of subjects: 78
Study 2021677 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (two dosage levels)
Number of subjects: 20
Study 2021677 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular cues to motion in depth (dark condition)
Number of subjects: 20
Study 2021677 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic depth information (uniform condition)
Number of subjects: 20
Study 6797661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (250-750 microgram/min)
Number of subjects: 9
Study 6797661 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (10-40 microgram/min)
Number of subjects: 9
Study 30660574 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-targeted cognitive training (TCT)
Number of subjects: 46
Study 30660574 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 46
Study 27605038 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (7% weight loss over 3-6 months)
Number of subjects: 52
Study 27605038 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (7% weight loss over 3-6 months)
Number of subjects: 52
Study 27605038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calorie restriction and exercise (7% weight loss over 3-6 months)
Number of subjects: 52
Study 27605038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 27281448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol Lozenges (AXL20) 20mg
Number of subjects: 2242
Study 27281448 — intervention group
Group type: COMPARATOR
Intervention: Placebo Lozenges (PL)
Number of subjects: 2242
Study 24407359 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPer (PTCA combined with RIPer, consisting of three cycles of 5‐min inflation and 5‐min deflation of an upper‐arm blood‐pressure cuff initiated before reperfusion)
Number of subjects: 151
Study 24407359 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPer+IPost (PTCA combined with RIPer and IPost, consisting of four cycles of 1‐min inflation and 1‐min deflation of the angioplasty balloon)
Number of subjects: 151
Study 24407359 — intervention group
Group type: COMPARATOR
Intervention: Control (PTCA alone)
Number of subjects: 151
Study 24407359 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPer and RIPer+IPost groups
Number of subjects: 151
Study 24407359 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPer+IPost and RIPer groups
Number of subjects: 151
Study 22983495 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-trial EEG using features from ERP components (P1, N1, P2a, P2b)
Number of subjects: 0
Study 22983495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of features from multiple ERP components
Number of subjects: 0
Study 19572937 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Number of subjects: 114
Study 19572937 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 2 g
Number of subjects: 114
Study 19572937 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen alone
Number of subjects: 114
Study 17312068 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 radioembolization
Number of subjects: 42
Study 15179650 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPI (1 uniform constant frequency component of 35Hz)
Number of subjects: 80
Study 15179650 — intervention group
Group type: EXPERIMENTAL
Intervention: EXPER (experimental form of stimulation with 5 frequency components: 125, 83, 50, 2.5, and 2Hz)
Number of subjects: 80
Study 15179650 — intervention group
Group type: COMPARATOR
Intervention: Both groups (EMPI and EXPER)
Number of subjects: 80
Study 11544790 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 M Multi‐Cure
Number of subjects: 20
Study 11544790 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC
Number of subjects: 20
Study 11544790 — intervention group
Group type: COMPARATOR
Intervention: Transbond (APC)
Number of subjects: 20
Study 9773174 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care based intervention involving a consultation with an exercise development officer and a personalized 10 week program to increase physical activity levels.
Number of subjects: 714
Study 9773174 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care based intervention
Number of subjects: 714
Study 9773174 — intervention group
Group type: COMPARATOR
Intervention: Control group (sent information on local leisure centres)
Number of subjects: 714
Study 8148353 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran oil
Number of subjects: 15
Study 8148353 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil
Number of subjects: 15
Study 8148353 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 15
Study 8148353 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 15
Study 3335991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivonex
Number of subjects: 10
Study 3335991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital
Number of subjects: 10
Study 1962595 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg daily
Number of subjects: 196
Study 1962595 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg daily
Number of subjects: 196
Study 1962595 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg daily
Number of subjects: 196
Study 73637 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic end‐to‐side portacaval shunt
Number of subjects: 89
Study 73637 — intervention group
Group type: COMPARATOR
Intervention: No shunt (control group)
Number of subjects: 89
Study 30730914 — intervention group
Group type: EXPERIMENTAL
Intervention: Women empowerment intervention
Number of subjects: 1463
Study 26656245 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal intervention (personalized call and mailed appointment reminder)
Number of subjects: 0
Study 26656245 — intervention group
Group type: COMPARATOR
Intervention: Automated intervention (automated call and mailed appointment reminder)
Number of subjects: 0
Study 26656245 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no additional intervention)
Number of subjects: 0
Study 26656245 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal intervention
Number of subjects: 0
Study 26656245 — intervention group
Group type: COMPARATOR
Intervention: Automated intervention
Number of subjects: 0
Study 26656245 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25546514 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 500
Study 25546514 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 500
Study 23704675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone (M)
Number of subjects: 699
Study 23704675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus intensive lifestyle program (M+L)
Number of subjects: 699
Study 23704675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone (M+R)
Number of subjects: 699
Study 23704675 — intervention group
Group type: COMPARATOR
Intervention: Control group (M, M+R, M+L)
Number of subjects: 699
Study 21422960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high adherence ≥80%)
Number of subjects: 13444
Study 19798914 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17909125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (fluoxetine + CBT)
Number of subjects: 327
Study 17909125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine therapy
Number of subjects: 327
Study 17909125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 327
Study 15911154 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural medicine rehabilitation (PT+CBT)
Number of subjects: 0
Study 15911154 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 0
Study 15911154 — intervention group
Group type: COMPARATOR
Intervention: Behaviour-oriented physiotherapy (PT)
Number of subjects: 0
Study 15911154 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group (CG)
Number of subjects: 0
Study 11306379 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2 excretion
Number of subjects: 129
Study 11306379 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-9 excretion
Number of subjects: 129
Study 11306379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no malignancy)
Number of subjects: 129
Study 9330417 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI albuterol through a neonatal Aerochamber with non-rebreathing valve
Number of subjects: 20
Study 9330417 — intervention group
Group type: COMPARATOR
Intervention: MDI albuterol through a neonatal Aerochamber without non-rebreathing valve
Number of subjects: 20
Study 9330417 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI albuterol through Babyhaler with one-way inspiratory valve
Number of subjects: 20
Study 9330417 — intervention group
Group type: COMPARATOR
Intervention: MDI albuterol through Babyhaler without one-way inspiratory valve
Number of subjects: 20
Study 8173883 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 gauge atraumatic needle
Number of subjects: 107
Study 8173883 — intervention group
Group type: COMPARATOR
Intervention: 22 gauge bevel tipped needle
Number of subjects: 107
Study 3236392 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI profiles from cluster analysis using average linkage method
Number of subjects: 196
Study 3236392 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI profiles from cluster analysis using Ward's hierarchical procedure
Number of subjects: 196
Study 3236392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of other substance abuse populations
Number of subjects: 196
Study 29345106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessed using the Mini Nutritional Assessment (MNA)
Number of subjects: 3472
Study 29345106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment
Number of subjects: 3472
Study 29260226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 300
Study 29260226 — intervention group
Group type: COMPARATOR
Intervention: No pessary (control)
Number of subjects: 300
Study 25951953 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational readiness intervention and integrated collaborative care service delivery intervention
Number of subjects: 0
Study 22527287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (DS) containing Red yeast rice (RYR), sugar cane‐derived policosanols (SCdP), and artichoke leaf extracts (ALEs)
Number of subjects: 39
Study 20602869 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group (n=34)
Number of subjects: 65
Study 20602869 — intervention group
Group type: COMPARATOR
Intervention: Information-only group (n=31)
Number of subjects: 65
Study 20602869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 19934666 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care management for depression for young-old patients
Number of subjects: 906
Study 19934666 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care management for depression for old-old patients
Number of subjects: 906
Study 16968421 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin omega
Number of subjects: 132
Study 16968421 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alpha
Number of subjects: 132
Study 15673097 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of prolonged cycling in the afternoon (2 h at 60% VO2max starting at 14:00)
Number of subjects: 8
Study 15673097 — intervention group
Group type: EXPERIMENTAL
Intervention: Two bouts of cycling (2 h at 60% VO2max starting at 09:00 and 14:00)
Number of subjects: 8
Study 15673097 — intervention group
Group type: COMPARATOR
Intervention: Resting trial
Number of subjects: 8
Study 10385662 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged therapy (IFN‐alpha for up to 32 weeks)
Number of subjects: 162
Study 10385662 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (IFN‐alpha for 16 weeks)
Number of subjects: 162
Study 8708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial strain
Number of subjects: 815
Study 8708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support withdrawal
Number of subjects: 815
Study 8708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Social undermining increase
Number of subjects: 815
Study 8708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced supportive behaviors
Number of subjects: 815
Study 8708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased undermining behaviors
Number of subjects: 815
Study 1839369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (N)
Number of subjects: 18
Study 1839369 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (ISM)
Number of subjects: 18
Study 6441537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg piribedil intravenously over a 15 min period
Number of subjects: 10
Study 6441537 — intervention group
Group type: COMPARATOR
Intervention: Dopamine receptor blocking agent, haloperidol (pretreated group)
Number of subjects: 10
Study 29783974 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prevention (Climate)
Number of subjects: 2190
Study 29783974 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective prevention (Preventure)
Number of subjects: 2190
Study 29783974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined universal and selective prevention (CAP)
Number of subjects: 2190
Study 29783974 — intervention group
Group type: COMPARATOR
Intervention: Health education as usual (Control)
Number of subjects: 2190
Study 29783974 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up (5- and 7-years post baseline)
Number of subjects: 2190
Study 27016084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus paclitaxel
Number of subjects: 529
Study 27016084 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 529
Study 27016084 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI‐SF worst pain
Number of subjects: 529
Study 27016084 — intervention group
Group type: EXPERIMENTAL
Intervention: RSCL activity level
Number of subjects: 529
Study 26581340 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 9
Study 26581340 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise
Number of subjects: 9
Study 26581340 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 9
Study 26581340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 9
Study 23827788 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine
Number of subjects: 494
Study 23827788 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine plus amodiaquine
Number of subjects: 494
Study 20006921 — intervention group
Group type: EXPERIMENTAL
Intervention: Z‐360 120 mg
Number of subjects: 33
Study 20006921 — intervention group
Group type: EXPERIMENTAL
Intervention: Z‐360 240 mg
Number of subjects: 33
Study 20006921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20006921 — intervention group
Group type: EXPERIMENTAL
Intervention: Z‐360 (both doses)
Number of subjects: 33
Study 18283231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program (29 sessions over 3 months)
Number of subjects: 191
Study 18283231 — intervention group
Group type: COMPARATOR
Intervention: Control activity (29 sessions over 3 months)
Number of subjects: 191
Study 18283231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 191
Study 18283231 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 191